These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 31679248)

  • 1. Evaluation of Nanocarrier-Based Dry Powder Formulations for Inhalation with Special Reference to Anti-Tuberculosis Drugs.
    Patil TS; Deshpande A; Shende PK; Deshpande S; Gaud R
    Crit Rev Ther Drug Carrier Syst; 2019; 36(3):239-276. PubMed ID: 31679248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting pulmonary tuberculosis using nanocarrier-based dry powder inhalation: current status and futuristic need.
    Patil TS; Deshpande AS; Deshpande S; Shende P
    J Drug Target; 2019 Jan; 27(1):12-27. PubMed ID: 29561179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dry powder inhalers of antitubercular drugs.
    Nainwal N; Sharma Y; Jakhmola V
    Tuberculosis (Edinb); 2022 Jul; 135():102228. PubMed ID: 35779497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential of dry powder inhalers for tuberculosis therapy: facts, fidelity and future.
    Mehta P; Bothiraja C; Kadam S; Pawar A
    Artif Cells Nanomed Biotechnol; 2018; 46(sup3):S791-S806. PubMed ID: 30307321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High dose dry powder inhalers to overcome the challenges of tuberculosis treatment.
    Momin MAM; Tucker IG; Das SC
    Int J Pharm; 2018 Oct; 550(1-2):398-417. PubMed ID: 30179703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhaled dry powder formulations for treating tuberculosis.
    Das S; Tucker I; Stewart P
    Curr Drug Deliv; 2015; 12(1):26-39. PubMed ID: 25030114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A facile one-step jet-milling approach for the preparation of proliposomal dry powder for inhalation as effective delivery system for anti-TB therapeutics.
    Srichana T; Eze FN; Thawithong E
    Drug Dev Ind Pharm; 2022 Oct; 48(10):528-538. PubMed ID: 36214588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rifampicin loaded chitosan nanoparticle dry powder presents an improved therapeutic approach for alveolar tuberculosis.
    Rawal T; Parmar R; Tyagi RK; Butani S
    Colloids Surf B Biointerfaces; 2017 Jun; 154():321-330. PubMed ID: 28363192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhalable poly(lactic-co-glycolic acid) (PLGA) microparticles encapsulating all-trans-Retinoic acid (ATRA) as a host-directed, adjunctive treatment for Mycobacterium tuberculosis infection.
    O'Connor G; Krishnan N; Fagan-Murphy A; Cassidy J; O'Leary S; Robertson BD; Keane J; O'Sullivan MP; Cryan SA
    Eur J Pharm Biopharm; 2019 Jan; 134():153-165. PubMed ID: 30385419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A review of co-milling techniques for the production of high dose dry powder inhaler formulation.
    Lau M; Young PM; Traini D
    Drug Dev Ind Pharm; 2017 Aug; 43(8):1229-1238. PubMed ID: 28367654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dry powder inhalable formulations for anti-tubercular therapy.
    Parumasivam T; Chang RY; Abdelghany S; Ye TT; Britton WJ; Chan HK
    Adv Drug Deliv Rev; 2016 Jul; 102():83-101. PubMed ID: 27212477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pulmonary drug delivery systems for tuberculosis treatment.
    Pham DD; Fattal E; Tsapis N
    Int J Pharm; 2015 Jan; 478(2):517-29. PubMed ID: 25499020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmaceutical aerosols for the treatment and prevention of tuberculosis.
    Hanif SN; Garcia-Contreras L
    Front Cell Infect Microbiol; 2012; 2():118. PubMed ID: 22973562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TPP-dendrimer nanocarriers for siRNA delivery to the pulmonary epithelium and their dry powder and metered-dose inhaler formulations.
    Bielski E; Zhong Q; Mirza H; Brown M; Molla A; Carvajal T; da Rocha SRP
    Int J Pharm; 2017 Jul; 527(1-2):171-183. PubMed ID: 28549971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intrinsic Antibacterial Activity of Nanoparticles Made of β-Cyclodextrins Potentiates Their Effect as Drug Nanocarriers against Tuberculosis.
    Machelart A; Salzano G; Li X; Demars A; Debrie AS; Menendez-Miranda M; Pancani E; Jouny S; Hoffmann E; Deboosere N; Belhaouane I; Rouanet C; Simar S; Talahari S; Giannini V; Villemagne B; Flipo M; Brosch R; Nesslany F; Deprez B; Muraille E; Locht C; Baulard AR; Willand N; Majlessi L; Gref R; Brodin P
    ACS Nano; 2019 Apr; 13(4):3992-4007. PubMed ID: 30822386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Solid Lipid Nanoparticle assemblies (SLNas) for an anti-TB inhalation treatment-A Design of Experiments approach to investigate the influence of pre-freezing conditions on the powder respirability.
    Maretti E; Rustichelli C; Romagnoli M; Balducci AG; Buttini F; Sacchetti F; Leo E; Iannuccelli V
    Int J Pharm; 2016 Sep; 511(1):669-679. PubMed ID: 27473279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How can nanoparticles contribute to antituberculosis therapy?
    Costa-Gouveia J; Aínsa JA; Brodin P; Lucía A
    Drug Discov Today; 2017 Mar; 22(3):600-607. PubMed ID: 28137645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and Characterization of a Dry Powder Formulation for Anti-Tuberculosis Drug Spectinamide 1599.
    Stewart IE; Lukka PB; Liu J; Meibohm B; Gonzalez-Juarrero M; Braunstein MS; Lee RE; Hickey AJ
    Pharm Res; 2019 Jul; 36(9):136. PubMed ID: 31321552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and characterization of spray-dried porous nanoaggregates for pulmonary delivery of anti-tubercular drugs.
    Kaur R; Garg T; Malik B; Gupta UD; Gupta P; Rath G; Goyal AK
    Drug Deliv; 2016; 23(3):882-7. PubMed ID: 24870203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ethambutol-Loaded Solid Lipid Nanoparticles as Dry Powder Inhalable Formulation for Tuberculosis Therapy.
    Nemati E; Mokhtarzadeh A; Panahi-Azar V; Mohammadi A; Hamishehkar H; Mesgari-Abbasi M; Ezzati Nazhad Dolatabadi J; de la Guardia M
    AAPS PharmSciTech; 2019 Feb; 20(3):120. PubMed ID: 30796625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.